Literature DB >> 31128214

Block of NF-kB signaling accelerates MYC-driven hepatocellular carcinogenesis and modifies the tumor phenotype towards combined hepatocellular cholangiocarcinoma.

Jiajia He1, Melanie Gerstenlauer1, Lap Kwan Chan1, Frank Leithäuser2, Matthew M Yeh3, Thomas Wirth4, Harald J Maier5.   

Abstract

Primary liver cancer ranks among the leading causes of cancer death worldwide. Risk factors are closely linked to inflammation, such as viral hepatitis and alcoholic as well as non-alcoholic steatohepatitis. Among the pathways involved in the pathogenesis of malignant liver tumors, dysregulation of NF-κB signaling plays a prominent role. It provides a link between inflammation and cancer. To examine the role of NF-κB in a MYC-induced model of hepatocellular carcinoma we deleted NEMO (IKKγ) specifically from hepatocytes. NEMO deletion accelerated tumor development and shortened survival, suggesting a tumor-suppressive function of NF-κB signaling. We observed increased proliferation, inflammation and fibrosis, as well as activation of MAPK and STAT signaling. Importantly, deletion of NEMO modified the tumor phenotype from hepatocellular carcinoma to combined hepatocellular cholangiocarcinoma. The intrahepatic cholangiocarcinoma tumor component showed increased expression of progenitor markers such as Sox9 and reduced expression of mature hepatic markers such as CPS1. In both cases tumorigenesis was reversible by turning off MYC expression. To our knowledge this is the first mouse model of combined hepatocellular cholangiocarcinoma and may provide insights into the development of this rare malignant tumor.
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma (HCC); Hepatocellular cholangiocarcinoma; MYC; NF-κB; NF-κB essential modulator (NEMO)

Mesh:

Substances:

Year:  2019        PMID: 31128214     DOI: 10.1016/j.canlet.2019.05.023

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  7 in total

Review 1.  Regular Aspirin Use Is Associated with a Reduced Risk of Hepatocellular Carcinoma (HCC) in Chronic Liver Disease: a Systematic Review and Meta-analysis.

Authors:  Jin Lin Tan; Sandeep Sidhu-Brar; Richard Woodman; Mohamed Asif Chinnaratha
Journal:  J Gastrointest Cancer       Date:  2022-06-18

2.  Gama-aminobutyric acid (GABA) alleviates hepatic inflammation via GABA receptors/TLR4/NF-κB pathways in growing-finishing pigs generated by super-multiparous sows.

Authors:  Shumin Zhang; Jinbiao Zhao; Jinhua Hu; Hengxun He; Yihan Wei; Linbao Ji; Xi Ma
Journal:  Anim Nutr       Date:  2022-02-17

Review 3.  Tumour evolution in hepatocellular carcinoma.

Authors:  Amanda J Craig; Johann von Felden; Teresa Garcia-Lezana; Samantha Sarcognato; Augusto Villanueva
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-12-02       Impact factor: 46.802

Review 4.  Oncogenic driver genes and tumor microenvironment determine the type of liver cancer.

Authors:  Gang Wang; Qian Wang; Ning Liang; Hongyuan Xue; Tao Yang; Xuguang Chen; Zhaoyan Qiu; Chao Zeng; Tao Sun; Weitang Yuan; Chaoxu Liu; Zhangqian Chen; Xianli He
Journal:  Cell Death Dis       Date:  2020-05-04       Impact factor: 8.469

5.  Loss of FoxA2 accelerates neoplastic changes in the intrahepatic bile duct partly via the MAPK signaling pathway.

Authors:  Junyi Shen; Yongjie Zhou; Xiaoyun Zhang; Wei Peng; Chihan Peng; Qiang Zhou; Chuan Li; Tianfu Wen; Yujun Shi
Journal:  Aging (Albany NY)       Date:  2019-11-05       Impact factor: 5.682

6.  Identification of CDCA2 as a Diagnostic and Prognostic Marker for Hepatocellular Carcinoma.

Authors:  Zhenjun Yu; Yu Zhang; Shuai Shao; Qi Liu; Yuhan Li; Xiaoxiao Du; Kun Zhang; Mengxia Zhang; Haixia Yuan; Qiang Yuan; Tong Liu; Yingtang Gao; Yijun Wang; Wei Hong; Tao Han
Journal:  Front Oncol       Date:  2021-10-01       Impact factor: 6.244

7.  Dissecting novel mechanisms of hepatitis B virus related hepatocellular carcinoma using meta-analysis of public data.

Authors:  Jihad Aljabban; Michael Rohr; Saad Syed; Eli Cohen; Naima Hashi; Sharjeel Syed; Kamal Khorfan; Hisham Aljabban; Vincent Borkowski; Michael Segal; Mohamed Mukhtar; Mohammed Mohammed; Emmanuel Boateng; Mary Nemer; Maryam Panahiazar; Dexter Hadley; Sajid Jalil; Khalid Mumtaz
Journal:  World J Gastrointest Oncol       Date:  2022-09-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.